Histone methyltransferases EHMT1 and EHMT2 (GLP/G9A) maintain PARP inhibitor resistance in high-grade serous ovarian carcinoma.

Watson ZL, Yamamoto TM, McMellen A, Kim H, Hughes CJ, Wheeler LJ, Post MD, Behbakht K, Bitler BG. Histone methyltransferases EHMT1 and EHMT2 (GLP/G9A) maintain PARP inhibitor resistance in high-grade serous ovarian carcinoma. Clin Epigenetics. 2019 11 27; 11(1):165.

View in: PubMed

subject areas

Animals
Cell Line, Tumor
Cystadenocarcinoma, Serous
Disease Progression
Drug Resistance, Neoplasm
Female
Gene Expression Profiling
Histocompatibility Antigens
Histone-Lysine N-Methyltransferase
Histones
Humans
Mass Spectrometry
Mice
Neoplasm Grading
Ovarian Neoplasms
Phthalazines
Piperazines
Poly(ADP-ribose) Polymerase Inhibitors
Sequence Analysis, RNA
Xenograft Model Antitumor Assays

authors with profiles

Kian Behbakht
Benjamin Guy Bitler
Zachary Levi Watson
Miriam Denise Post
Alexandra McMellen
Lindsay Joyce Brubaker